Theravance Biopharma completes Phase 3 enrollment for ampreloxetine in nOH due to MSA; topline Q1 2026

Theravance Biopharma, Inc.

Enrollment completed in open-label portion of pivotal Phase 3 CYPRESS study (NCT05696717) for nOH due to MSA.
Expected topline results in Q1 2026; if positive, plans for expedited NDA submission and priority FDA review.
Ampreloxetine has Orphan Drug Designation in the U.S.; addresses ~40,000 patients with symptomatic nOH due to MSA.
Primary endpoint is change in OHSA composite score from randomized-withdrawal baseline to Week 8.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.